Abstract
Phase 1/2 study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): The KEYNOTE-046 trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have